Moreover, genetic alterations commonly seen in MDS, such as mutations in SF3B1, disrupt normal splicing and lead to increased degradation of SMAD7, thereby amplifying TGF-β signaling and further impeding erythroid maturation [29–31]. The gene discussed is SF3B1; the disease is myelodysplastic syndrome.